Marker Therapeutics (MRKR) Competitors

$1.44 -0.02 (-1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$1.46 +0.03 (+1.74%)

As of 06:01 PM Eastern

MRKR vs. VRCA, FTLF, BMEA, ANIX, and ONCY

Should you buy Marker Therapeutics stock or one of its competitors? MarketBeat compares Marker Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marker Therapeutics include Verrica Pharmaceuticals (VRCA), FitLife Brands (FTLF), Biomea Fusion (BMEA), Anixa Biosciences (ANIX), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry.

How does Marker Therapeutics compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Verrica Pharmaceuticals has a net margin of -47.97% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

In the previous week, Marker Therapeutics had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 2 mentions for Marker Therapeutics and 1 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat Marker Therapeutics' score of 1.44 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Very Positive
Marker Therapeutics	Positive

Marker Therapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.86	-$17.89M	-$1.03	N/A
Marker Therapeutics	$3.55M	6.76	-$12.16M	-$0.61	N/A

Verrica Pharmaceuticals presently has a consensus price target of $14.50, indicating a potential upside of 144.52%. Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 594.44%. Given Marker Therapeutics' higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Verrica Pharmaceuticals has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Verrica Pharmaceuticals and Marker Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Marker Therapeutics compare to FitLife Brands?

Marker Therapeutics (NASDAQ:MRKR) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

Marker Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

FitLife Brands has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.76	-$12.16M	-$0.61	N/A
FitLife Brands	$81.46M	1.28	$6.33M	$0.60	18.52

Marker Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 594.44%. FitLife Brands has a consensus target price of $21.50, suggesting a potential upside of 93.52%. Given Marker Therapeutics' higher possible upside, equities analysts plainly believe Marker Therapeutics is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, FitLife Brands had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for FitLife Brands and 2 mentions for Marker Therapeutics. FitLife Brands' average media sentiment score of 1.60 beat Marker Therapeutics' score of 1.44 indicating that FitLife Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Marker Therapeutics	Positive
FitLife Brands	Very Positive

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 2.3% of FitLife Brands shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by insiders. Comparatively, 61.7% of FitLife Brands shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

FitLife Brands has a net margin of 6.64% compared to Marker Therapeutics' net margin of -343.03%. FitLife Brands' return on equity of 18.31% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
FitLife Brands	6.64%	18.31%	8.21%

Summary

FitLife Brands beats Marker Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Marker Therapeutics compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Marker Therapeutics has higher revenue and earnings than Biomea Fusion. Marker Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Marker Therapeutics	$3.55M	6.76	-$12.16M	-$0.61	N/A

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Biomea Fusion has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Biomea Fusion presently has a consensus target price of $8.50, suggesting a potential upside of 558.91%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 594.44%. Given Marker Therapeutics' higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Biomea Fusion has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

In the previous week, Biomea Fusion had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 2 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.44 beat Biomea Fusion's score of 0.80 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biomea Fusion	Positive
Marker Therapeutics	Positive

Summary

Marker Therapeutics beats Biomea Fusion on 8 of the 15 factors compared between the two stocks.

How does Marker Therapeutics compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Anixa Biosciences had 3 more articles in the media than Marker Therapeutics. MarketBeat recorded 5 mentions for Anixa Biosciences and 2 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.44 beat Anixa Biosciences' score of 0.57 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anixa Biosciences	Positive
Marker Therapeutics	Positive

Anixa Biosciences has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Anixa Biosciences has higher earnings, but lower revenue than Marker Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	516.78	-$10.93M	-$0.31	N/A
Marker Therapeutics	$3.55M	6.76	-$12.16M	-$0.61	N/A

Anixa Biosciences has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Anixa Biosciences' return on equity of -71.12% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Anixa Biosciences presently has a consensus target price of $8.50, suggesting a potential upside of 166.46%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 594.44%. Given Marker Therapeutics' higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Anixa Biosciences beats Marker Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Marker Therapeutics compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Marker Therapeutics has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Marker Therapeutics	$3.55M	6.76	-$12.16M	-$0.61	N/A

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oncolytics Biotech has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Oncolytics Biotech currently has a consensus price target of $8.50, indicating a potential upside of 835.92%. Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 594.44%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, equities research analysts clearly believe Oncolytics Biotech is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Oncolytics Biotech has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

In the previous week, Oncolytics Biotech had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 4 mentions for Oncolytics Biotech and 2 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 1.44 beat Oncolytics Biotech's score of 1.16 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncolytics Biotech	Positive
Marker Therapeutics	Positive

Summary

Marker Therapeutics beats Oncolytics Biotech on 9 of the 15 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRKR vs. The Competition

Export

Metric	Marker Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.34M	$3.02B	$6.85B	$12.44B
Dividend Yield	N/A	2.08%	2.68%	8.43%
P/E Ratio	-2.36	18.77	27.04	24.38
Price / Sales	6.76	344.35	524.25	93.48
Price / Cash	N/A	56.83	48.59	59.36
Price / Book	1.43	4.20	10.80	6.33
Net Income	-$12.16M	$65.13M	$3.59B	$331.02M
7 Day Performance	-14.29%	-3.41%	-2.24%	-1.09%
1 Month Performance	4.35%	2.41%	3.12%	-0.49%
1 Year Performance	-8.86%	20.10%	26.30%	19.90%

Marker Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRKR Marker Therapeutics	3.2201 of 5 stars	$1.44 -1.4%	$10.00 +594.4%	-14.6%	$24.34M	$3.55M	N/A	60	Positive News Short Interest Decrease
VRCA Verrica Pharmaceuticals	3.2355 of 5 stars	$6.25 +2.0%	$14.50 +132.0%	-26.6%	$107.38M	$35.58M	N/A	40	Positive News
FTLF FitLife Brands	4.6254 of 5 stars	$11.07 -1.1%	$21.50 +94.3%	-14.1%	$104.83M	$81.46M	18.48	20	News Coverage Positive News Short Interest Decrease
BMEA Biomea Fusion	2.4503 of 5 stars	$1.42 +2.5%	$8.50 +500.7%	-33.5%	$102.30M	N/A	N/A	50	News Coverage
ANIX Anixa Biosciences	4.0689 of 5 stars	$3.00 -1.6%	$8.50 +183.3%	-2.5%	$102.06M	$210K	N/A	5	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRKR) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marker Therapeutics (MRKR) Competitors

MRKR vs. VRCA, FTLF, BMEA, ANIX, and ONCY

How does Marker Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Marker Therapeutics compare to FitLife Brands?

Summary

How does Marker Therapeutics compare to Biomea Fusion?

Summary

How does Marker Therapeutics compare to Anixa Biosciences?

Summary

How does Marker Therapeutics compare to Oncolytics Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marker Therapeutics (MRKR) Competitors

MRKR vs. VRCA, FTLF, BMEA, ANIX, and ONCY

How does Marker Therapeutics compare to Verrica Pharmaceuticals?

Is VRCA or MRKR more profitable?

Does the media favor VRCA or MRKR?

Which has higher valuation and earnings, VRCA or MRKR?

Do analysts recommend VRCA or MRKR?

Which has more risk & volatility, VRCA or MRKR?

Do institutionals and insiders believe in VRCA or MRKR?

Summary

How does Marker Therapeutics compare to FitLife Brands?

Which has more risk and volatility, MRKR or FTLF?

Which has preferable valuation & earnings, MRKR or FTLF?

Do analysts recommend MRKR or FTLF?

Does the media refer more to MRKR or FTLF?

Do insiders and institutionals have more ownership in MRKR or FTLF?

Is MRKR or FTLF more profitable?

Summary

How does Marker Therapeutics compare to Biomea Fusion?

Which has higher earnings & valuation, BMEA or MRKR?

Do institutionals & insiders have more ownership in BMEA or MRKR?

Is BMEA or MRKR more profitable?

Do analysts prefer BMEA or MRKR?

Which has more risk and volatility, BMEA or MRKR?

Does the media prefer BMEA or MRKR?

Summary

How does Marker Therapeutics compare to Anixa Biosciences?

Do insiders & institutionals have more ownership in ANIX or MRKR?

Does the media refer more to ANIX or MRKR?

Which has more risk and volatility, ANIX or MRKR?

Which has preferable earnings and valuation, ANIX or MRKR?

Is ANIX or MRKR more profitable?

Do analysts rate ANIX or MRKR?

Summary

How does Marker Therapeutics compare to Oncolytics Biotech?

Which has higher valuation & earnings, ONCY or MRKR?

Do institutionals & insiders hold more shares of ONCY or MRKR?

Is ONCY or MRKR more profitable?

Do analysts prefer ONCY or MRKR?

Which has more risk and volatility, ONCY or MRKR?

Does the media prefer ONCY or MRKR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools